What happened with CLLS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cellectis uses its TALEN gene-editing technology to modify healthy donors’ T cells into potential cancer treatments. Its UCART candidates are designed to be stored and supplied as ready-made treatments, rather than made from each patient’s own cells. The company develops its own candidates, initially focused on blood cancers, and also works on gene therapies for other diseases.
Most revenue comes from collaboration agreements, with AstraZeneca the main source of research activity. AstraZeneca reimburses agreed research costs and can pay to take exclusive development and commercialization rights to selected candidates. Cellectis also licenses technology and product rights to partners such as Allogene and Iovance. These arrangements can bring payments when development or commercial milestones are reached, and royalties if licensed products are sold.
Cellectis has no approved products and earns no revenue from therapeutic product sales. Bringing its own treatments to market requires further trials, regulatory approval and manufacturing scale-up. Its business also depends on partners advancing licensed candidates, while continued development requires additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cellectis’s results hinge on AstraZeneca-funded research and clinical progress in its own and licensed therapies, with privately held Servier also controlling CD19 rights tied to substantial potential milestones and royalties.
AstraZeneca pays Cellectis to research and manufacture up to ten cell and gene therapy candidates, supporting current collaboration revenue and potential future milestones and royalties. Work under this agreement was the main driver of Cellectis’s 2025 revenue growth, making research activity and AstraZeneca’s decisions to take candidates forward the news to watch.
Allogene Therapeutics, Inc. uses Cellectis’s TALEN gene-editing technology to develop donor-cell cancer treatments, potentially paying Cellectis milestones and royalties while competing with its own off-the-shelf therapies. Progress in these licensed oncology candidates matters on both sides: it can advance Cellectis’s licensing income and strengthen a rival.
Caribou Biosciences, Inc. competes with Cellectis in gene-edited, off-the-shelf CAR T-cell treatments for blood cancers, using its chRDNA editing platform rather than TALEN. Its vispa-cel trial in relapsed or refractory B-cell non-Hodgkin lymphoma offers a concrete comparison for Cellectis’s lymphoma programs.
CRISPR Therapeutics develops gene-edited CAR T-cell cancer therapies that compete with Cellectis’s approach, making their clinical results useful benchmarks against each other. For this comparison, watch its oncology CAR T candidates rather than its approved blood-disorder treatment CASGEVY.
Iovance Biotherapeutics, Inc. pays to use Cellectis’s TALEN technology to edit immune cells found inside tumors, creating annual license payments and potential milestones and sales royalties for Cellectis. Watch the edited-cell candidate IOV-4001, which switches off the gene coding for PD-1; the license covers TALEN-modified TIL products, not all Iovance sales.
Fate Therapeutics, Inc. competes with Cellectis in engineered, off-the-shelf cancer cell therapies, but makes its cells from induced pluripotent stem cells rather than donor-derived T cells. Its HER2-targeting solid-tumor candidate FT825 / ONO-8250 is one to watch alongside Cellectis’s preclinical solid-tumor programs.
Autolus Therapeutics plc sells AUCATZYL, a treatment made from a patient’s own T cells, competing with donor-cell CD19 therapies developed using Cellectis technology. Its sales to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia provide a commercial reference for those still-developing therapies.
Legend Biotech’s donor-cell CAR T programs for lymphoma and myeloma overlap with Cellectis’s own and licensed cancer therapies. Watch its Phase 1 trials in China, including candidates targeting CD19/BCMA and CD19/CD70, for progress in these competing approaches.
Lyell Immunopharma, Inc. competes with Cellectis’s blood-cancer and solid-tumor programs through CAR T-cell candidates designed to recognize multiple targets. Watch its CD19/CD20 lymphoma candidate ronde-cel and solid-tumor candidate LYL273 for clinical progress in that multi-target approach.
Sana Biotechnology, Inc. and Cellectis develop donor-cell T-cell therapies, so Sana’s clinical progress offers a comparison for Cellectis’s competing cancer-treatment approach. Sana has not commercialized a product or generated revenue from any source, making development news—not sales—the relevant signal.
AstraZeneca PLC earningsAZN
AstraZeneca’s report can show whether its cell and gene therapy collaboration is advancing, which matters for Cellectis’s research-service revenue and potential future milestones.
Look for disclosure that the collaboration’s research continues or that AstraZeneca advances a candidate. Ongoing work can support Cellectis’s research-service revenue as it performs the work; advancing a candidate keeps potential milestones and royalties in play. A pause or no sign of advancement would leave less support for Cellectis’s collaboration income and future payments.
Cellectis S.A. earningsThis company
Cellectis has no approved products and relies on collaboration payments; its report will show whether research income continues to offset part of development costs and how quickly cash is being used.
Read collaboration revenue alongside operating cash flow. Rising collaboration revenue with a contained operating cash outflow would show completed partner work helping fund research; falling collaboration revenue and a wider cash outflow would show that partner income is uneven while Cellectis must still finance clinical development from its resources.
